Insights

In this episode of Cambridge Gravity Encounters, Emily James and Jan Venne sit down with Allan to explore his extraordinary journey in science. They discuss his early years, his time as Director of the Wellcome Sanger Institute, his time at the University of…

Our CEO Allan Bradley shares an overview of T-Therapeutics, our technology and how the team is seeking to reshape the clinical landscape for cancer patients.

Phoebe Lee, a scientist in our Pipeline Expression team, gives a flavour of T-Therapeutics as a workplace, as well as the broader Cambridge life sciences ecosystem.

Camillo Moschner, PhD, a scientist in our Synthetic Biology & Automation department, talks about the importance of bringing biology and engineering closer together.

Amy Li, Director for Drug Discovery at T-Therapeutics, outlines how discoveries from the antibody field have informed the OpTiMus® platform and engineering of humanised TCRs.

Michael Casey, Principal Data Scientist, outlines how T-Therapeutics is building a soluble TCR ‘factory’ to reliably develop new medications for a range of indications.

What’s it like moving from academia to a lab role at a growing biotech? Ying Ying (Joyce) Tan, a scientist on the Target Discovery team, gives her perspective on the culture of collaboration at T-Therapeutics.

Ruben Cabanillas, Senior Director of Translational Medicine, discusses the importance of keeping the patient at the front of mind at every stage of research and development.

T-Therapeutics’ CEO Allan Bradley shares his thoughts on why a diverse, expert team with a shared vision is so vital to the future success of the business.

Dr David Hung has joined T-Therapeutics as Chairman of its Board of Directors. In this video, which accompanied the announcement, Dr Hung explains his decision: “I have always wanted to be on the cutting-edge of science and transform the practice of medicine. I…